Probiotic peanut allergy treatment: Chr. Hansen enters new partnership


18 Apr 2018 --- Chr. Hansen's probiotic strain, Lactobacillus rhamnosus (LGG), can potentially play a part in peanut allergy treatment, according to new data. Prota Therapeutics, developer of oral immunotherapies to treat food allergies, has partnered with Chr. Hansen, Danish food ingredients producer, to assess LGG in a clinical trial to develop a treatment for the allergy. Chr. Hansen tells NutritionInsight that the partnership is in effect as from today, and strengthens the position of Chr. Hansen in a market expected to grow to €10 billion by 2025.

An effective therapy to treat peanut allergies is now a realistic target. Chr. Hansen is the ideal partner for us in this next step, both as the owner of one of the key components in the therapeutic product – LGG – and as a leading expert in microbial solutions, says Dr. Suzanne Lipe, CEO at Prota Therapeutics.

“Chr. Hansen has demonstrated the capability to deliver a pharmaceutical quality product that can be regulated as a biological therapeutic product. Together with our proprietary peanut protein formulation, we aim to progress this through to commercialization of a treatment for peanut allergies, she adds. 

Thomas Gundelund Rasmussen, Director, Human Health and Microbiome Innovation tells NutritionInsight that regarding the medicine hitting the shelves, the process could take some time: It will be approximately three years for the phase three clinical study, which is followed by discussions with the US FDA. After which, Prota intends to submit a Biologics License Application to FDA.

However, he predicts that the company expects that these developments will, further strengthen the value and demand for LGG outside the Pharma world, thus strengthening our existing probiotics business for non-pharma applications.

Continuing clinical trials
Numerous studies have highlighted the therapeutic potential of specific bacteria in preventing and treating metabolic, gastrointestinal and other diseases. Investigating particular bacteria for the treatment of food allergies is an area that has recently gained momentum.

Prota Therapeutics is pioneering a new form of oral immunotherapy treatment. It combines Chr. Hansen’s specially formulated LGG probiotic strain with targeted doses of proprietary formulations of peanut protein. The procedure is designed to reprogram the immune system’s response to peanuts and eventually develop tolerance.

Building upon earlier trials conducted at the Murdoch Children’s Research Institute, Prota Therapeutics is progressing towards a large-scale Phase III clinical trial, under a US Investigational New Drug Application (IND). 

The aim is to commercialize a medicinal product using a new pharmaceutical-grade therapeutic dosage form for treating peanut allergy and to explore indications for treating other food allergies.

Chr. Hansen has the ability to maximize the value of a probiotic strain through our deep experience in microbial process development and formulation, our focus on quality, and our global reach. The partnership with Prota Therapeutics is part of our strategy to become the partner of choice for companies wanting to develop new generations of therapeutic microbes, says Christian Barker, Executive Vice President, Health & Nutrition at Chr. Hansen.

Speaking to our sister website, FoodIngredientsFirst, earlier this month, Christoffer Lorenzen, EVP Food Cultures & Enzymes at Chr. Hansen stated that they were excited about the use of microorganisms and the huge potential they hold for innovation.

“We want to enter into more partnerships in the food sector and to cater to dialogs related to health and wellness where the customer’s emphasis is on quality. Additionally, as a company, we have a lot of the focus on health and wellness in our Health and Nutrition business unit where we are working on both within the dietary supplements and infant nutrition space and also in the human microbiome space, on how a good bacteria impacts human health, he added.

The LGG strain is the world’s best documented probiotic strain and has been used in food and dietary supplements since 1990. Chr. Hansen fully acquired LGG from Valio in 2016, to further strengthen its microbial platform.

Additionally, earlier this month they reported that their Food Cultures and Enzymes unit helped bolster their solid organic overall revenue growth of nine percent.

Food allergies
Approximately 220-250 million people globally suffer from food allergies, an increase of 350 percent over the past 20 years. Furthermore, peanut allergy is the most common cause of anaphylaxis, a life-threatening allergic reaction, and one of the most common causes of death from food allergy. More than 3 million Americans suffer from peanut allergy3 resulting in a global peanut allergy therapeutics market estimated to reach more than US$10 billion by 2052.

In other allergen news, NutritionInsight has reported on intensifying calls for sesame inclusion in US allergen labeling rules.

By Laxmi Haigh 

To contact our editorial team please email us at

Related Articles

Health & Nutrition News

Joint health: “boomer” and “millennial” demographics hold future potential, says Lonza exec

19 Oct 2018 --- The global market for joint health supplements is increasing, driven by the large “baby boomer” population seeking to maintain their bone health and “millennials” high rate of supplement use. This is according to Dominik Mattern, Associate Director and Head of Business Development at Lonza. During a NutritionInsight webinar presented yesterday, entitled Driving growth in the joint health category: UC-II undenatured Type II collagen for joint support, Mattern highlighted the shifting market dynamics which is supporting the popularity of ingredients for joint health such as Lonza's UC-II undenatured Type II collagen.

Health & Nutrition News

Krill harvesting: Aker BioMarine to build new support vessel in China

18 Oct 2018 --- Aker BioMarine is set to build its newest support vessel in China. After signing a memorandum of understanding with representatives from the China Overseas Development Association (CODA), Matts Johansen, CEO of Aker BioMarine noted: “This is the beginning of a unique collaboration bringing together innovative technologies and high-tech competencies from both Norwegian and Chinese companies.”

Health & Nutrition News

Children with allergies nine times more likely to develop emerging, severe chronic food allergy, warns study

16 Oct 2018 --- Children with known skin, food and respiratory allergies should be screened for an emerging, chronic food allergy called eosinophilic esophagitis (EoE), warns a study published in the Journal of Allergy and Clinical Immunology: In Practice. Pediatric allergists who analyzed a group of children from birth to adolescence say that EoE should be considered a later component of the “allergic march” – the natural progression in which many children develop a series of allergies.

Health & Nutrition News

Stain-free turmeric: AFS launches free-flowing curcumin ingredient

16 Oct 2018 --- Applied Food Sciences (AFS) is set to debut a free-flowing curcumin extract, CurcuFlow, designed for manufacturers to achieve a cleaner, stain-free turmeric production. Due to the lengthy cleanup times, some companies refuse to take on turmeric projects with traditional curcumin ingredients. Production runs involving traditional turmeric extracts can incur post-production clean times that are 5 to 6 times longer than when running other ingredients.

Health & Nutrition News

Microbiota and sports performance: Calls for greater NPD innovation from Olympic Gold skater

12 Oct 2018 --- Probiotics hold major untapped potential in the sports nutrition arena, with greater scientific support for efficacy coming on stream in just the past 4 to 5 years. But there is still plenty of innovation potential to fill. This is according to Dutch Olympic Gold Medal speed skater and newfound nutrition entrepreneur, Mark Tuitert. 

More Articles